3Q sales, trends for key Bristol-Myers medicines
Global sales of key Bristol-Myers Squibb drugs in 2012's third quarter:
Drug name Use 2012 Change from 2011
Plavix Blood thinner $64 million Down 96 percent
Avapro/Avalide High blood pressure $95 million Down 56 percent
Reyataz HIV/AIDS $363 million Down 7 percent
Abilify Psychiatric disorders $676 million Down 2 percent
Erbitux Various cancers $173 million Up 1 percent
Sustiva HIV/AIDS $370 million Up 3 percent
Baraclude Hepatitis B $346 million Up 11 percent
Sprycel Leukemia $263 million Up 25 percent
Orencia Rheumatoid arthritis $307 million Up 32 percent
Onglyza Type 2 diabetes $178 million Up 40 percent
Yervoy Melanoma $179 million Up 48 percent
___
Source: Bristol-Myers Squibb Co.